Stock fact sheet · data as of
Corcept Therapeutics Incorporated (CORT): fair value, margin of safety and Wheel Score
Healthcare · Medical - Pharmaceuticals · United States · High Growth
Is CORT undervalued?
Corcept Therapeutics Incorporated (CORT) closed at 113.37 on 16 Oct 2026, 366% above the GLS average fair value of 24.31. 8 of the 8 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.
The 8 models disagree widely: EPV gives 5.79 while DCF gives 51.79. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files CORT under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for CORT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 51.79 | -54% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 8.86 | -92% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 29.80 | -74% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 13.02 | -89% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 31.09 | -73% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 14.31 | -87% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 39.83 | -65% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 5.79 | -95% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 2.74 | -98% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 125.33 | +11% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - CORT passes 6 of the nine Piotroski tests, which passes the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 4.8 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are high - ROIC 15.2%, ROE 15.4%, ROA 11.9% - with debt at 0.01 times equity and a free-cash-flow yield of 0.9%.
Corcept Therapeutics Incorporated pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 2 Oct 2026.
| Piotroski F-score | 6 / 9 | ROIC | 15.2% |
|---|---|---|---|
| GLS Moat | 4.8 / 10 | ROE | 15.4% |
| Debt / equity | 0.01 | ROA | 11.9% |
| Free-cash-flow yield | 0.9% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 57: Fair
CORT scores 57 out of 100 on the Wheel Score (Fair band, 50-64): a usable but unremarkable fit for the wheel strategy. The parts: Value 0/25, Health 13/20, Moat 7/15, Premium 19/20, Stability 17/20. Value (0/25) is where the points are missing.
Implied volatility is 64% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (19 of 20) because volatility this high usually comes with a reason. Chain open interest is 36,366 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 668k shares a day on a market cap of $12.3B, with a beta of 0.45 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 17 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -366% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 7 / 15 | moat 4.8/10 | |
| Premium | 19 / 20 | implied volatility 64% | |
| Stability | 17 / 20 | 668k shares/day, $12.3B cap, beta 0.45 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 4 Nov 2026 (after the close), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Pharmaceuticals
The 12 companies below are the closest to Corcept Therapeutics Incorporated by market cap within the Medical - Pharmaceuticals industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc | 79.94 | 46.31 | -73% | 55Fair | $6.2B |
| RPRX Royalty Pharma plc | 58.99 | 64.00 | +8% | 76Good | $26.3B |
| RTEZ Rest Ez Inc. | 70.00 | 0.0327 | -213797% | 12No options | $4.2B |
| LQDA Liquidia Corporation | 34.78 | 29.69 | -17% | 52Fair | $3.1B |
| PBH Prestige Consumer Healthcare Inc. | 48.40 | 105.25 | +54% | 76Good | $2.3B |
| HELP Helus Pharma Inc. | 11.05 | 3.18 | -248% | 28Weak | $685M |
| HITI High Tide Inc. | 2.56 | 5.54 | +54% | 45Weak | $228M |
| CTOR Citius Oncology, Inc. | 0.7460 | 0.1046 | -613% | 9No options | $69M |
| GWLL Goldenwell Biotech, Inc. | 0.6000 | 0.0007 | -87122% | 3No options | $59M |
| COSM Cosmos Health Inc. | 0.3364 | - | - | 36Weak | $34M |
| NSRX Nasus Pharma Ltd. | 3.17 | 0.0567 | -5486% | 4No options | $27M |
| SCYX SCYNEXIS, Inc. | 3.96 | - | - | 32Weak | $25M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about CORT
Is CORT undervalued right now?
No: at 113.37 the stock trades 366% above the GLS average fair value of 24.31 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of CORT and what does it mean?
CORT scores 57 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for CORT?
24.31 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Corcept Therapeutics Incorporated report earnings next?
The next earnings report is due on 4 Nov 2026 (after the close), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does CORT have listed options, and how liquid are they?
Yes. The nightly snapshot found 510 listed contracts with 36,366 open interest across all expiries and implied volatility of 64% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.